Joel Barrish

133 posts

Joel Barrish

Joel Barrish

@jcbarrish

Passionate about Drug Discovery and having an impact on patients in need. Cofounder & CSO at Jnana Tx

Katılım Şubat 2012
223 Takip Edilen186 Takipçiler
Joel Barrish retweetledi
No Patient Left Behind
No Patient Left Behind@NPLB_org·
Autoimmune diseases afflict 45 million Americans—and it requires a collective community effort to change that. @NPLB_org's Community Quest video shows how investors, innovators, regulators, patients, insurers—and you—make new treatments possible, accessible, and affordable.
English
3
16
19
4.6K
Joel Barrish retweetledi
Giulio Superti-Furga
Giulio Superti-Furga@giuliosf·
Finally! It is happening! After 6 years of hard work by formidable teams in 13 institutions @RESOLUTE_IMI, we have ordered and validated the results and are able to share the FOUR (4) papers aimed at assigning functional properties to each human SLC #membranetransporter
Giulio Superti-Furga tweet media
English
7
79
379
45.6K
Joel Barrish retweetledi
No Patient Left Behind
No Patient Left Behind@NPLB_org·
45 MILLION Americans suffer from autoimmune diseases—and instead of helping, some health plans make it WORSE. 💥 People pay their premiums, then get slapped with sky-high out-of-pocket costs for their prescription meds. 😡 This is unacceptable. If you or someone you know is fighting an autoimmune disease AND their health plan to get the medicine they need, here’s a simple way to help: Ask if your employer offers first-dollar coverage for prescribed medicines - and if not, why not? 💔 Stand up and help #FixInsurance NOW. 💪 #InsuranceReform #Firstdollarcoverage #OOP #autoimmune #chronicdisease #lupus #rheumatoidarthritis #scleroderma #Multiplesclerosis #firstdollarcoverage
English
9
42
170
13K
Joel Barrish retweetledi
No Patient Left Behind
No Patient Left Behind@NPLB_org·
You should never have to fight cancer AND your insurance company. Half of cancer patients abandon treatment when out-of-pocket costs exceed $2,000. Prescribed medicines, “covered” by an insurer, should be affordable with low or no out-of-pocket cost. Let’s #FixInsurance
English
15
76
254
28.9K
Joel Barrish retweetledi
No Patient Left Behind
No Patient Left Behind@NPLB_org·
If you have Type 1 diabetes, insulin keeps you alive. Why do health plans make you “prove” you need it by charging a copay on top of premiums? No Patient Left Behind is working to #FixInsurance & cap high out-of-pocket costs for prescribed medicines. #T1D #diabetes
English
31
149
589
84.9K
Joel Barrish retweetledi
Peter Kolchinsky
Peter Kolchinsky@PeterKolchinsky·
What no one has yet recognized about Biosecurity is that Americans won't care about who invents or doesn't invent new medicines if they don't think they will be able to afford them anyways. rapport.bio/all-stories/us… We need pro-AFFORDABLE innovation policy, not just pro-innovation policy, which means capping what insurance can patients in charge out of pocket costs. What's the point of charging a copay for chemo? Who over-utilizes that? Like if the copay were zero, what reasonable thinks people will fake cancer to joyride chemo? Unfortunately, many Democrats are still pushing price controls. With the election approaching, listen to how they will keep pounding on the idea pricing all drugs 9 years after launch... or 5 years... or right off the bat. Sure, maybe they want to protect the US biomedical innovation ecosystem from China, but only so that they can undermine it themselves with price controls and show voters ("I did that!"). These politicians will cynically sell out Americans' biomedical future for their votes today. A small, smart group of Democrats and many Republicans understand that innovation is driven by patent-lengths of market-based rewards, not government price controls. They are wisely proposing a 9-13 fix to the IRA to make sure that all drugs get up to 13 years of their patent life (which averages 14 year normally) after launch. That fix is essential to restore incentives for small molecules of diseases of aging and align with the pro-US-innovation intent of the Biosecurity Act. @IAmBiotech @PhRMA @NPLB_org
English
1
40
66
18.7K
Joel Barrish
Joel Barrish@jcbarrish·
@DMHuryn @Roche So awesome to come full circle and now share this honor with @DMHuryn! I just hope that like me it was so long ago that she’s forgotten most of our conversations in the car…
English
0
0
4
83
Joel Barrish retweetledi
Jnana Therapeutics
Jnana Therapeutics@jnanatx·
On #RareDiseaseDay, we’re spotlighting PKU, a rare genetic metabolic disease in which high levels of phenylalanine accumulate in the blood, which can result in neurological impairment & neuropsychological complications. Read about our clinical candidate: bit.ly/3xU87EP
Jnana Therapeutics tweet media
English
0
3
8
1.7K
Joel Barrish
Joel Barrish@jcbarrish·
Congratulations to the @jnanatx team for their outstanding work leading to the FIH with JNT-517. We’re thrilled to have Bain Capital join Jnana’s Board and are looking forward to working with them to continue to advance Jnana.
Jnana Therapeutics@jnanatx

Jnana is thrilled to announce a $107M Series C financing and initiation of our Phase 1 clinical trial in #PKU. The financing will support the PKU program and our preclinical programs in immune-mediated diseases and cancer. Learn more: bit.ly/3UYTiuc #BiotechNews

English
1
2
16
0
Joel Barrish
Joel Barrish@jcbarrish·
@MarkLautens Very sad - Dave was a giant in the field, both science and as a person. He touched many of us as young scientists who weren’t even in his group. First met him at a Natural Products GRC in 1986, will never forget it - or him.
English
0
0
3
0
Mark Lautens OC
Mark Lautens OC@MarkLautens·
Breaking news courtesy of Kevin Campos and Dave MacMillan, from Sally Evans. Dave passed away last night. This pic that they included is how Dave looked during my days in his group. Circa 1985-87
Mark Lautens OC tweet media
English
32
123
554
0